Focal Segmental Glomerulosclerosis (FSGS)
9
4
4
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
11.1%
1 terminated out of 9 trials
75.0%
-11.6% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (9)
Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
Immunophenotyping Profiling in Patients With Primary Nephrotic Syndrome
SLIT ABS: Study on Patients With Autoimmune Podocytopathy
A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis
Rituximab Treatment of Focal Segmental Glomerulosclerosis
Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment
Raman Spectroscopy Diagnosis of Kidney Diseases
A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)
A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147